Orchard Therapeutics Plc (ORTX) Tops Q4 EPS by 147c

Orchard Therapeutics Plc (NASDAQ: ORTX) reported Q4 EPS of ($1.69), $1.47 better than the analyst estimate of ($3.16). Revenue for the quarter came in at $2.1 million, versus $0 reported last year.

“In 2018 we expanded and advanced our portfolio of autologous, ex vivo, hematopoietic stem cell gene therapies and established the capabilities to scale a global, fully integrated biopharmaceutical company serving patients. This year, we plan to build on these successes and further establish Orchard as a leader in the gene therapy field,” said Mark Rothera, president and chief executive officer of Orchard. “Our priorities include advancing our ADA-SCID and MLD programs towards regulatory filings in 2020 and preparing the ground for their commercialization while extending our clinical stage pipeline. This work underpins our vision of delivering therapies that have the potential to transform the lives of patients with rare, life-threatening diseases around the globe with a single treatment.”

For earnings history and earnings-related data on Orchard Therapeutics Plc (ORTX) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• BT Brands posts Q2 profit, cuts costs as restaurant sales dip
• Home Depot beats estimates, reaffirms fiscal 2026 guidance